Birgit Spänkuch

1.0k total citations
21 papers, 823 citations indexed

About

Birgit Spänkuch is a scholar working on Molecular Biology, Oncology and Cell Biology. According to data from OpenAlex, Birgit Spänkuch has authored 21 papers receiving a total of 823 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Molecular Biology, 11 papers in Oncology and 10 papers in Cell Biology. Recurrent topics in Birgit Spänkuch's work include Microtubule and mitosis dynamics (10 papers), Cancer-related Molecular Pathways (7 papers) and RNA Interference and Gene Delivery (5 papers). Birgit Spänkuch is often cited by papers focused on Microtubule and mitosis dynamics (10 papers), Cancer-related Molecular Pathways (7 papers) and RNA Interference and Gene Delivery (5 papers). Birgit Spänkuch collaborates with scholars based in Germany, Switzerland and Ireland. Birgit Spänkuch's co-authors include Klaus Strebhardt, Klaus Langer, I Steinhauser, Elisabeth Kurunci‐Csacsko, M. Kaufmann, Manfred Kaufmann, Juping Yuan, Gisbert Schneider, Yves Matthess and Ewgenij Proschak and has published in prestigious journals such as Angewandte Chemie International Edition, Biomaterials and Cancer Research.

In The Last Decade

Birgit Spänkuch

21 papers receiving 809 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Birgit Spänkuch Germany 14 557 282 227 196 92 21 823
Anandhkumar Raju Singapore 13 701 1.3× 151 0.5× 182 0.8× 198 1.0× 142 1.5× 15 1.1k
Anne Margriet Heijink Netherlands 12 896 1.6× 412 1.5× 138 0.6× 75 0.4× 88 1.0× 13 1.2k
Seung Woo Chung South Korea 20 493 0.9× 257 0.9× 131 0.6× 270 1.4× 290 3.2× 47 1.0k
Nicolas Floc’h United Kingdom 14 587 1.1× 464 1.6× 85 0.4× 57 0.3× 82 0.9× 30 1.2k
Arnaldur Hall Denmark 15 692 1.2× 115 0.4× 66 0.3× 134 0.7× 112 1.2× 21 956
Ada Gjyrezi United States 9 338 0.6× 236 0.8× 93 0.4× 181 0.9× 146 1.6× 15 833
Florian Reichart Germany 17 641 1.2× 253 0.9× 63 0.3× 142 0.7× 154 1.7× 24 1.1k
Michal Stark Israel 18 627 1.1× 279 1.0× 63 0.3× 95 0.5× 101 1.1× 31 1.1k
Barbara J. Bailey United States 15 370 0.7× 206 0.7× 128 0.6× 79 0.4× 59 0.6× 26 732
Andreas F. B. Räder Germany 11 509 0.9× 177 0.6× 52 0.2× 139 0.7× 129 1.4× 13 887

Countries citing papers authored by Birgit Spänkuch

Since Specialization
Citations

This map shows the geographic impact of Birgit Spänkuch's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Birgit Spänkuch with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Birgit Spänkuch more than expected).

Fields of papers citing papers by Birgit Spänkuch

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Birgit Spänkuch. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Birgit Spänkuch. The network helps show where Birgit Spänkuch may publish in the future.

Co-authorship network of co-authors of Birgit Spänkuch

This figure shows the co-authorship network connecting the top 25 collaborators of Birgit Spänkuch. A scholar is included among the top collaborators of Birgit Spänkuch based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Birgit Spänkuch. Birgit Spänkuch is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Hemmerich, Peter, et al.. (2015). Survival of primary, but not of cancer cells after combined Plk1-HDAC inhibition. Oncotarget. 6(28). 25801–25814. 4 indexed citations
2.
Schneider, Gisbert, et al.. (2014). Vanillin-derived antiproliferative compounds influence Plk1 activity. Bioorganic & Medicinal Chemistry Letters. 24(21). 5063–5069. 15 indexed citations
3.
Spänkuch, Birgit, Tiago Rodrigues, Heiko Zettl, et al.. (2012). Drugs by Numbers: Reaction‐Driven De Novo Design of Potent and Selective Anticancer Leads. Angewandte Chemie International Edition. 52(17). 4676–4681. 20 indexed citations
4.
Spänkuch, Birgit, Tiago Rodrigues, Heiko Zettl, et al.. (2012). Wirkstoffe nach Zahlen: reaktionsbasierter De‐novo‐Entwurf von potenten und selektiven Leitstrukturen für die Krebsforschung. Angewandte Chemie. 125(17). 4774–4779. 9 indexed citations
5.
Proschak, Ewgenij, et al.. (2011). Fate of primary cells at the G1/S boundary after polo-like kinase 1 inhibition by SBE13. Cell Cycle. 10(4). 708–720. 8 indexed citations
6.
Schneider, Gisbert, Tim Geppert, Markus Hartenfeller, et al.. (2011). Reaction-Driven De Novo Design, Synthesis and Testing of Potential Type II Kinase Inhibitors. Future Medicinal Chemistry. 3(4). 415–424. 26 indexed citations
7.
Rödel, Franz, Gianni Capalbo, Manfred Kaufmann, et al.. (2010). Polo-Like Kinase 1 as Predictive Marker and Therapeutic Target for Radiotherapy in Rectal Cancer. American Journal Of Pathology. 177(2). 918–929. 57 indexed citations
8.
Proschak, Ewgenij, et al.. (2010). Biological impact of freezing Plk1 in its inactive conformation in cancer cells. Cell Cycle. 9(4). 761–774. 25 indexed citations
9.
Proschak, Ewgenij, et al.. (2010). SBE13, a newly identified inhibitor of inactive polo-like kinase 1. Journal of Cheminformatics. 2(S1). 1 indexed citations
10.
Steinhauser, I, Klaus Langer, Klaus Strebhardt, & Birgit Spänkuch. (2009). Uptake of plasmid-loaded nanoparticles in breast cancer cells and effect on Plk1 expression. Journal of drug targeting. 17(8). 627–637. 17 indexed citations
11.
Proschak, Ewgenij, et al.. (2009). Identification and Validation of a Potent Type II Inhibitor of Inactive Polo‐like Kinase 1. ChemMedChem. 4(11). 1806–1809. 30 indexed citations
12.
Spänkuch, Birgit, et al.. (2008). Downregulation of Plk1 Expression By Receptor-Mediated Uptake of Antisense Oligonucleotide-Loaded Nanoparticles. Neoplasia. 10(3). 223–234. 39 indexed citations
13.
Steinhauser, I, Klaus Langer, Klaus Strebhardt, & Birgit Spänkuch. (2008). Effect of trastuzumab-modified antisense oligonucleotide-loaded human serum albumin nanoparticles prepared by heat denaturation. Biomaterials. 29(29). 4022–4028. 70 indexed citations
14.
Spänkuch, Birgit & Klaus Strebhardt. (2008). Combinatorial Application of Nucleic Acid-Based Agents Targeting Protein Kinases for Cancer Treatment. Current Pharmaceutical Design. 14(11). 1098–1112. 6 indexed citations
15.
Spänkuch, Birgit, Elisabeth Kurunci‐Csacsko, M. Kaufmann, & Klaus Strebhardt. (2007). Rational combinations of siRNAs targeting Plk1 with breast cancer drugs. Oncogene. 26(39). 5793–5807. 80 indexed citations
16.
Spänkuch, Birgit, et al.. (2006). Down-regulation of Polo-like Kinase 1 Elevates Drug Sensitivity of Breast Cancer CellsIn vitroandIn vivo. Cancer Research. 66(11). 5836–5846. 66 indexed citations
17.
Steinhauser, I, Birgit Spänkuch, Klaus Strebhardt, & Klaus Langer. (2006). Trastuzumab-modified nanoparticles: Optimisation of preparation and uptake in cancer cells. Biomaterials. 27(28). 4975–4983. 180 indexed citations
18.
Spänkuch, Birgit & Klaus Strebhardt. (2005). RNA Interference-Based Gene Silencing in Mice: The Development of a Novel Therapeutical Strategy. Current Pharmaceutical Design. 11(26). 3405–3419. 12 indexed citations
19.
Matthess, Yves, et al.. (2005). Conditional inhibition of cancer cell proliferation by tetracycline-responsive, H1 promoter-driven silencing of PLK1. Oncogene. 24(18). 2973–2980. 39 indexed citations
20.
Yuan, Juping, Andrea Krämer, Yves Matthess, et al.. (2005). Stable gene silencing of cyclin B1 in tumor cells increases susceptibility to taxol and leads to growth arrest in vivo. Oncogene. 25(12). 1753–1762. 110 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Anandhkumar Raju Breakdown of academic impact, for papers by Anne Margriet Heijink Breakdown of academic impact, for papers by Seung Woo Chung Breakdown of academic impact, for papers by Nicolas Floc’h Breakdown of academic impact, for papers by Arnaldur Hall Breakdown of academic impact, for papers by Ada Gjyrezi Breakdown of academic impact, for papers by Florian Reichart Breakdown of academic impact, for papers by Michal Stark Breakdown of academic impact, for papers by Barbara J. Bailey Breakdown of academic impact, for papers by Andreas F. B. Räder
Rankless by CCL
2026